InterVenn Biosciences

InterVenn Biosciences is a CAP accredited, CLIA-certified laboratory, focused on precision medicine diagnostic products and services that leverages glycoproteomics and incorporates a powerful AI platform, to detect the earliest warning signs of disease.
InterVenn was co-founded by Nobel Laureate, Dr. Carolyn Bertozzi, world-class scientist and distinguished professor, Dr. Carlito Lebrilla, and leading AI / Machine-Learning expert Aldo Carrascoso on the belief that no one should ever be blindsided by disease.

Defining a new era of precision medicine:
InterVenn has pioneered a proprietary technology platform, GlycoVision, enabling our biopharma and academic partners to tap into the glycoproteome at an unprecedented and clinically meaningful scale. Now, the relevance of this new layer of biology can be interrogated from as little as 50 µL of serum or plasma to deliver meaningful insights into disease. GlycoVision is capable of producing a robust pipeline of powerful translational and clinical applications, ranging from target discoveries, to early disease screening and monitoring as well as companion diagnostics. 

Harnessing the Immune System to Detect Early Warning Signs of CRC:
Early next year, we expect to bring our glycoproteomics science to patients via GlycoKnow Colon*, a simple blood test that detects early warning signs of colon cancer. The GlycoKnow Colon test will measure glycosylation profiles of glycoproteins in serum/blood that are associated with pre-cancerous  tissue changes which could lead to colon cancer and cancerous changes that will be able to detect CRC.

The GlycoKnow Colon test will be recommended for patients at increased risk for developing colorectal cancer, (high-risk is defined by having a family or personal history of advanced adenomas or colorectal cancer) or people ages 45-75 that have not been screened by other methods.

Save Time and Improve Access:
GlycoKnow Colon will eliminate the need for prior day prep, stool collection, and a day off from work. The blood draw can be done the same day a person has an appointment with their physician or in combination with other scheduled blood work. To find out more, please join our mailing list to be notified on important updates regarding GlycoKnow Colon: https://go.venn.bio/glycoknow-sign-up 

*Our tests have not been cleared or approved by the U.S. Food and Drug Administration. InterVenn’s clinical laboratory is regulated under CLIA to perform high-complexity testing. Our tests are not intended for clinical purposes.  The GlycoKnow Colon test is not yet available.